title: Molecular response prediction in multimodality treatment for adenocarcinoma of the esophagus and esophagogastric junction.
abstract: Cancers arising from the esophagus are becoming more common in the United States and Europe. In 2009, an estimate of 14,530 new cases will be diagnosed and more than 90% will die of their disease. Esophageal cancer is currently the most rapidly increasing cancer in the western world and is coinciding with a shift in histological type and primary tumor location. Despite recent improvements in the detection, surgical resection, and (radio-) chemotherapy, the overall survival (OS) of esophageal cancer remains relatively poor. It is becoming increasingly apparent that neoadjuvant chemoradiation followed by surgery may be beneficial in terms of increasing resectability and OS compared to surgery alone. Results from clinical trials are encouraging; however, they also demonstrated that only patients with major histopathological response (pCR) will benefit from neoadjuvant therapy. In addition, these therapies are expensive and the prognoses of patients who do not respond to trimodality treatment strategies appear to be inferior to that of patients who had surgery alone. Accordingly, the development of validated predictive molecular markers may not only be helpful in identifying EA patients who are more likely to respond, but they will also be critical in selecting more efficient treatment strategies with the means of a tailored, targeted, and effective therapy to the molecular profile of both the patient and their disease while minimizing and avoiding life-threatening toxicities.
authors.affiliation: Department of Visceral- and Transplantation Surgery, University Hospital of Zurich, Raemistrasse 100, 8091, Zurich, Switzerland. georg.lurje@usz.ch
authors.forename: Georg
authors.initials: G
authors.lastname: Lurje
authors.forename: Heinz-Josef
authors.initials: HJ
authors.lastname: Lenz
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000628:therapy*; D003131:Combined Modality Therapy; D018899:CpG Islands; D066246:ErbB Receptors / Q000235:genetics; D004938:Esophageal Neoplasms / Q000235:genetics / Q000628:therapy*; D004943:Esophagogastric Junction; D020869:Gene Expression Profiling; D016158:Genes, p53; D006801:Humans; D013274:Stomach Neoplasms / Q000235:genetics / Q000628:therapy*
chemical_list: D066246:ErbB Receptors